HanchorBio Announces Commitments Made for Initial Listing on the Innovation Board and Subsequent Implementation Status
HanchorBio Inc. has disclosed the commitments made during its initial listing application on the Tai… · 2026-07-23
漢康-KY創 News Releases
FBD Biologics Limited, Subsidiary of Han Kang-KY, Announces Strategic MOU with Innovative Biologics (Shanghai) Co., Ltd.
FBD Biologics Limited, a subsidiary of Han Kang-KY, has signed a strategic Memorandum of Understandi… · 2026-07-08
HanchorBio Announces Receipt of U.S. FDA Type C Meeting Minutes Supporting HCB101 Development Path in Second-Line Gastric/GEJ Cancer
HanchorBio Inc. has received the official minutes from a Type C meeting with the U.S. FDA regarding … · 2026-06-30
HanKang-KY Chuang Announces Board Resolution to Issue Restricted Employee Stock Rights
HanKang-KY Chuang's board has resolved to issue 1,501,036 restricted shares to employees at prices r… · 2026-06-18
Han Kang-KY Chuang Announces Board Resolution to Issue Employee Stock Options Below Market Price
Han Kang-KY Chuang's board has resolved to issue employee stock options below market price to incent… · 2026-06-18
Hankang-KY Chuang Announces Board Resolution to Convene 2026 First Extraordinary Shareholders' Meeting
Hankang-KY Chuang has announced the convening of its 2026 First Extraordinary Shareholders' Meeting … · 2026-06-18
Hankang-KY Announces Resignation of Director
Hankang-KY announced that its director, He Dong-guang, resigned effective June 17, 2026, due to pers… · 2026-06-17
[Hankang-KY] May 2026 Revenue at NT$0.00 Billion (YoY Change N/A)
Hankang-KY (Code: 7827), a company in the biotechnology and medical industry, announced its monthly … · 2026-05-01